



FY26 RESULTS RELEASE AND INVESTOR CALL

21 August 2026, Adelaide, Australia: Mayne Pharma Group Limited (Mayne Pharma or the Company) (ASX: MYX), announces that it will release its financial statements for the full year ended 30 June 2026 (FY26) on Thursday, 27 August 2026.

Mayne Pharma's CEO Mr Aaron Gray and CFO Mr Griffin Buchanan will host a webcast of the results at 9.30am AEST on Thursday, 27 August 2026 (7.30pm Eastern US Time on Wednesday, 26 August 2026).

Participants can register for the webcast / teleconference by navigating to:
<https://s1.c-conf.com/diamondpass/10055595-h1qn7y.html>

Click [here](#) to view the announcement on Investor Hub.

- ENDS -

For further information contact:

Dr Tom Duthy
Investor Relations
+61 402 493 727
ir@maynepharma.com

Authorised for release to the ASX by the Board Chair.

Follow us on [LinkedIn](#)

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma is a leader in dermatology and women's health in the United States and also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.